FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Their core work

FISEVI is the research management foundation for the public health system in Seville, Spain. It provides the administrative, legal, and clinical infrastructure that enables hospital-based researchers to participate in EU-funded projects — particularly multi-centre clinical trials, epidemiological studies, and health data initiatives. Their core value lies in connecting Andalusian hospital networks (patients, clinicians, clinical data) to large European research consortia, acting as the institutional bridge between frontline healthcare delivery and international research collaboration.

What they specialise in

How they've shifted over time

FISEVI's early H2020 involvement (2018–2019) spanned diverse topics: health informatics and FAIR data, rare tumor clinical networks, and wearable prosthetic sensors — reflecting a broad service role supporting whichever hospital researchers secured EU funding. From 2021 onward, a clear concentration emerged around infectious diseases, antimicrobial resistance, pandemic preparedness, and cardio-oncology, suggesting the foundation built dedicated capacity in these areas, likely accelerated by COVID-19. Their 2022 coordinated project in cellular senescence marks a step toward independent research leadership beyond clinical trial infrastructure.

FISEVI is consolidating around infectious disease preparedness and cardio-oncology while beginning to build independent research coordination capacity, making them increasingly relevant for clinical trial consortia in southern Europe.

How they like to work

FISEVI operates overwhelmingly as a third party (7 of 8 projects), meaning they typically provide clinical sites, patient cohorts, or data under a lead partner's coordination — a role common for hospital-affiliated research foundations. Their single coordinated project (SENOXIA, an MSCA fellowship) suggests early-stage ambition to lead, but their primary value today is as a reliable clinical node. With 107 unique partners across 32 countries, they are well-networked but not a consortium architect — they are invited because of what their hospitals can contribute.

Despite their third-party role, FISEVI has connected with 107 distinct partners across 32 countries, reflecting the large multi-centre consortia they participate in. Their network is pan-European with likely clinical trial connections extending to Latin America through the SELNET sarcoma project.

What sets them apart

FISEVI's distinctive value is access to the Seville public hospital system — one of the largest in Andalusia — which provides patient populations, clinical data, and trial sites that are essential for multi-centre health research. For consortium builders, this means a single entry point to southern Spanish clinical infrastructure without negotiating separately with individual hospitals. Their third-party model also means low administrative overhead for lead partners: FISEVI handles the institutional complexity so researchers can focus on science.

Highlights from their portfolio

• SENOXIA
  Their only coordinated project — an MSCA fellowship studying hypoxia and senescence in lung cancer and Alzheimer's, signaling a move toward independent research leadership.
• VACCELERATE
  Part of Europe's emergency COVID-19 vaccine trial acceleration platform, demonstrating FISEVI's capacity to mobilize clinical trial infrastructure under crisis conditions.
• ECRAID-Base
  A long-running (2021–2026) European infectious disease research alliance, positioning FISEVI as a sustained contributor to pandemic preparedness infrastructure.